Results 151 to 160 of about 3,081 (193)

Investigation of the mechanism of hypertension caused by BTKi in the treatment of hematologic diseases [PDF]

Frontiers in Pharmacology
Bruton’s tyrosine kinase inhibitors (BTKis) have made substantial impacts on the treatment of B-cell malignancies like chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Therapeutic benefits aside, the clinical use of BTKis comes with several side effects, of which hypertension (HTN) is quite common and serious and of significant ...
Jiayi Xu, Junling Lin, Haojian Gan, Qingjian He, WenJuan Wang, Yuanhua Liu   +5 more
exaly   +5 more sources

Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis [PDF]

Blood Advances, 2022
Susan O'Brien, Elizabeth Brem
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Zulassung des ersten BTKI der 2. Generation

InFo Hämatologie + Onkologie, 2021
Gunter Springer
exaly   +2 more sources

Abstract 4679: Molecular pathology and BTKi pharmacology of DLBCL-PDXs

Cancer Research, 2023
Abstract Diffuse large B-cell lymphoma (DLBCL), the largest subtype of non-Hodgkin’s lymphoma (NHL, ~40%), is a heterogeneous disease with diverse pathogenesis, represented by different subtypes/genotypes based on lymphoma related specific gene expression profiling according to cell-of-origin (COO) and/or mutation profiles, likely ...
Jingjing Wang, Yueying Wang, Wubin Qian, Jia Xue, Sheng Guo, Likun Zhang, Henry Qixiang Li   +6 more
openaire   +1 more source

Abstract 4725: The epigenetic determinants of BTKi efficacy in chronic lymphocytic leukemia

Cancer Research, 2023
Abstract Introduction: The introduction of Bruton’s tyrosine kinase (BTK) inhibitors (BTKi) to target B cell receptor (BCR) pathways in chronic lymphocytic leukemia (CLL) has significantly improved clinical responses. However, the effectiveness of BTKi is limited by the development of adaptive drug resistance.
Zhiquan Wang, Huihuang Yan, Justin C. Boysen, Esteban Braggio, Sameer A. Parikh, Neil E. Kay   +5 more
openaire   +1 more source

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon

Blood Advances
Thomas E Lew, Sasanka M Handunnetti, Andrew W. Roberts   +2 more
exaly   +5 more sources

Cardiac Monitoring of Patients on Btki for Chronic Lymphocytic Leukemia

Blood
Background: The first-in-class Bruton tyrosine kinase inhibitor (BTKi) ibrutinib is associated with an increased risk of atrial fibrillation (AF), ventricular arrhythmia, and sudden death. While next-generation BTKis, acalabrutinib and zanubrutinib, are more selective, growing evidence has ...
Christine Gruessner, Alessandra Brofferio, Emily Tomasulo, Jeanine Superata, Shellin Jose, Susan Soto, Said Hafizullah Fayaz, Christopher Pleyer, Pia Nierman, Ovsanna Melikyan, Adrian Wiestner, Mark Haigney, Clare Sun   +12 more
openaire   +1 more source

Upfront continuous BTK inhibitor (BTKi) versus time-limited venetoclax-BTKi combinations in CLL across IGHV subgroups: Results of an indirect analysis

Blood
Abstract The optimal first-line treatment for patients with treatment-naïve (TN), TP53 wild-type chronic lymphocytic leukemia (CLL) remains an area of ongoing research. A key factor influencing treatment selection is the immunoglobulin heavy-chain variable region gene (IGHV) mutation status ...
Stefano Molica, David Allsup, Annalisa Chiarenza, Diana Giannarelli   +3 more
openaire   +1 more source

BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies

Blood Reviews
Targeted therapies, consisting of Bruton tyrosine kinase inhibitors (BTKis) or BCL-2 inhibitors, are the mainstay of contemporary treatments for chronic lymphocytic leukemia (CLL). The most common adverse effects (AEs) of BTKis are fatigue, bruising, infection, hematological and cardiovascular AEs.
Sofija, Kozarac, Vojin, Vukovic, Michael, Fradley, Darko, Antic   +3 more
openaire   +2 more sources

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma

Blood
Abstract Introduction: cBTKi have made a substantial impact in pts w/ MCL, but pts who develop PD while on treatment w/ cBTKi have historically had poor responses to subsequent lines of therapy (LOT).
Paolo Lopedote, Adrienne Nedved, Lu Chen, Marcus Watkins, Arian Roua, Muhamad Alhaj Moustafa, Seyi Abidoye, Yun Choi, Georgios Pongas, Tony Zhuang, Jean Clement, Megan Searssmith, Laura Sun, Hannah Willis, Brad Kahl, David Bond, Javier Munoz, Izidore S. Lossos, Craig Portell, Michael Wang, Nilanjan Ghosh, Jonathon Cohen, Peter Martin, Jeremy Abramson, Anne Beaven, Patrick Reagan, Daniel Ermann, Taylor Brooks, Ashlee Joseph, Nazila Shafagati, Daniel McLoughlin, Kira Rosenlind, Brian Hill, Nina Wagner-Johnston, Anita Kumar, Umar Farooq, Reem Karmali, Tanaya Shree, Matthew Lunning, Stacy Pak, Alexey Danilov, Yucai Wang, Tycel Phillips   +42 more
openaire   +1 more source